The prevalence of latent/chronic infection in liver transplant candidates in Taleghani Hospital of Tehran, Iran, from 2020 until 2021
- PMID: 37070118
- PMCID: PMC10105496
- DOI: 10.22037/ghfbb.v16i1.2664
The prevalence of latent/chronic infection in liver transplant candidates in Taleghani Hospital of Tehran, Iran, from 2020 until 2021
Abstract
Aim: The present study aimed to study the prevalence of various latent infections in pre-transplanted patients.
Background: Due to chronic immunosuppressive therapy, patients receiving organ transplants are at risk for reactivation of various infections. Due to the complications in the course of diagnosing and treating the post-transplant infection, screening transplant recipients and donors is vital.
Methods: This retrospective cohort study was performed between March 2020 and 2021. A total of 193 patients receiving a liver transplant in Taleghani Hospital, Tehran, Iran were enrolled.
Results: One-hundred and three (53.4%) patients were men, with an average age of 48.4 ± 13.3 years. Among viruses, 177 (91.7%) patients had a positive IgG titer for CMV. Anti-EBV IgG was positive in 169 (87.6%) patients. One-hundred and seventy-five (90.7%) patients had a positive IgG titer for the VZV. One-hundred and sixty-six (86.0%) cases had positive IgG anti-HSV antibodies. According to our findings, none of the patients were infected with HIV, but 9 (4.7%) cases and 141 (73.1%) had positive anti-HCV and anti-HAV IgG antibodies, respectively. HBV surface (HBs) antigen was also reported positive in 17 (8.8%) patients, while the HBs antibody was positive in 29 (15.0%) patients.
Conclusion: In our study, most of the patients had positive serology for latent viral infections such as CMV, EBV, VZV, and HSV, but the prevalence of latent tuberculosis and viral hepatitis was low among transplant candidates.
Keywords: CMV IgG; Infection reactivation; Latent infections; Liver transplant; Transplant candidate.
Conflict of interest statement
All authors have no relevant financial interests to be declared.
Similar articles
-
Seroprevalence of cytomegalovirus in donors & opportunistic viral infections in liver transplant recipients.Indian J Med Res. 2017 Apr;145(4):558-562. doi: 10.4103/ijmr.IJMR_1024_14. Indian J Med Res. 2017. PMID: 28862190 Free PMC article.
-
Hepatitis B Reactivation in Liver Transplant Recipients With Hepatitis B Virus Core Antibody Positive Grafts: a Retrospective Study.J Clin Exp Hepatol. 2020 Nov-Dec;10(6):548-554. doi: 10.1016/j.jceh.2020.05.001. Epub 2020 May 8. J Clin Exp Hepatol. 2020. PMID: 33311891 Free PMC article.
-
Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?Transplant Proc. 2009 Sep;41(7):2761-3. doi: 10.1016/j.transproceed.2009.07.057. Transplant Proc. 2009. PMID: 19765428
-
Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.PLoS Med. 2023 Mar 15;20(3):e1004196. doi: 10.1371/journal.pmed.1004196. eCollection 2023 Mar. PLoS Med. 2023. PMID: 36920988 Free PMC article.
-
[Evaluation of viral hepatitis in solid organ transplantation].Acta Med Croatica. 2014 Apr;68(2):151-9. Acta Med Croatica. 2014. PMID: 26012153 Review. Croatian.
References
-
- Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. J Immunol. 2019;3:14–21.
-
- Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VR. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ. 2022;25:230–237. - PubMed
-
- Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150:252–259. - PubMed
LinkOut - more resources
Full Text Sources